62 results on '"Halabi, Susan"'
Search Results
2. Pembrolizumab Plus Platinum-Based Chemotherapy as First-Line Systemic Therapy in Advanced Penile Cancer (HERCULES / LACOG 0218): A Multicenter, Single-Arm, Phase 2 Trial
3. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
4. Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium
5. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
6. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma
7. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
8. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021
9. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
10. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
11. Corrigendum to 'What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021' [Eur Urol 2022].
12. Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 2022]
13. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel
14. Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA Vaccines
15. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
16. Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary
17. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine
18. Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint–responsive Subset?
19. In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions
20. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer
21. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
22. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
23. Best (but oft-forgotten) practices: sample size and power calculation for a dietary intervention trial with episodically consumed foods
24. Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel
25. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
26. Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer
27. Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer
28. Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]
29. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
30. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
31. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
32. Residential metal contamination and potential health risks of exposure in adobe brick houses in Potosí, Bolivia
33. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
34. A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)
35. Refining Prognosis in Lung Cancer
36. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration–resistant prostate cancer
37. Independent data monitoring committees: An update and overview
38. A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
39. Estimations of historical atmospheric mercury concentrations from mercury refining and present-day soil concentrations of total mercury in Huancavelica, Peru
40. Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer
41. Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia
42. Combination External Beam Radiation and Brachytherapy Boost With Androgen Suppression for Treatment of Intermediate-Risk Prostate Cancer: Long-Term Results of CALGB 99809
43. The Importance of Identifying and Validating Prognostic Factors in Oncology
44. The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate Cancer
45. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
46. Arsenic Trioxide in Recurrent Urothelial Cancer: A Cancer and Leukemia Group B Phase II Trial (CALGB 99903)
47. Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment
48. Combination External Beam Radiation and Brachytherapy Boost With Androgen Suppression for Treatment of Intermediate-Risk Prostate Cancer: An Initial Report of CALGB 99809
49. A Phase II Study of Estramustine, Docetaxel, and Exisulind in Patients with Hormone- Refractory Prostate Cancer: Results of Cancer and Leukemia Group B Trial 90004
50. Tumor Volume Changes on 1.5 Tesla Endorectal MRI During Neoadjuvant Androgen Suppression Therapy for Higher-Risk Prostate Cancer and Recurrence in Men Treated Using Radiation Therapy Results of the Phase II CALGB 9682 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.